Tag Archive for: MYC
Phase 1 Trial: PMR-116, Targeting The Undruggable MYC Oncogene
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxUTRxM1-18: mRNA Drug Targeting c-MYC Offers New Hope for Prostate Cancer Patients
/0 Comments/in mRNA, Preclinical Research/by MaxPhase 1 Trial: CTS2190 Targets Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: The COSMYC Trial, ZEN-3694 Combination With BAT
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- UPDATE 2: More Data About ATNM-400 Antibody Radioconjugate Therapy August 1, 2025
- New Combination Therapy Shows Potential for Treating MYC-Driven Cancers August 1, 2025
- Phase 1: SYN608 Targets DNA Repair in HRR-Deficient Prostate and Other Solid Tumors July 30, 2025
- Phase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab July 30, 2025